Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Buy" by Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has been assigned a consensus rating of "Buy" from the seven research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $18.08.

A number of equities analysts have weighed in on ROIV shares. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Roivant Sciences Trading Down 1.6 %

Shares of NASDAQ:ROIV traded down $0.18 during trading on Wednesday, hitting $10.79. 15,739,544 shares of the company's stock traded hands, compared to its average volume of 5,623,817. Roivant Sciences has a 52 week low of $9.93 and a 52 week high of $13.06. The company has a market cap of $7.70 billion, a price-to-earnings ratio of -71.93 and a beta of 1.26. The company has a 50-day moving average price of $10.78 and a 200-day moving average price of $11.47.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, analysts predict that Roivant Sciences will post -0.92 earnings per share for the current fiscal year.

Remove Ads

Insider Activity at Roivant Sciences

In other news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares of the company's stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eric Venker sold 176,900 shares of the stock in a transaction on Friday, December 27th. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00. Following the transaction, the chief operating officer now owns 668,680 shares in the company, valued at $7,903,797.60. The trade was a 20.92 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,875,586 shares of company stock worth $21,491,661. Company insiders own 7.90% of the company's stock.

Institutional Trading of Roivant Sciences

Several large investors have recently modified their holdings of the stock. FMR LLC grew its holdings in shares of Roivant Sciences by 0.3% during the 4th quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after purchasing an additional 156,527 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after purchasing an additional 2,404,232 shares in the last quarter. State Street Corp boosted its stake in Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after buying an additional 1,118,561 shares in the last quarter. Patient Square Capital LP grew its position in Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after acquiring an additional 251,535 shares during the last quarter. Finally, Two Seas Capital LP raised its stake in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after acquiring an additional 442,914 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.